↓ Skip to main content

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

patent
1 patent

Readers on

mendeley
79 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951
Published in
Haematologica, July 2017
DOI 10.3324/haematol.2017.165845
Pubmed ID
Authors
Abstract

Asparaginase is an essential component of combination chemotherapy for childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma. The value of asparaginase was further addressed in a group of non-very high risk patients by comparing a prolonged (long-asparaginase) versus standard (short-asparaginase) native E.coli asparaginase treatment through a randomized question as part of the phase III 58951 trial of the European Organisation for Research and Treatment of Cancer Children's Leukemia Group. The main endpoint was disease-free survival. Overall, 1,552 patients were randomly assigned to long-asparaginase (775 patients) or short-asparaginase (777 patients). Patients with grade≥2 allergy to native E.coli asparaginase were switched to equivalent doses of Erwinia or pegylated E.coli asparaginase. The 8-year disease-free survival rate (±standard error) was 87.0+/-1.3% in the long-asparaginase and 84.4±1.4% in the short-asparaginase group (hazard ratio:0.87, P=0.33) and the 8-year overall survival rate was 92.6&+/-1.0% and 91.3+/-1.2% respectively (hazard ratio:0.89, P=0.53). An exploratory analysis suggested that the impact of long-asparaginase was beneficial in National Cancer Institute standard risk group regarding disease-free survival (hazard ratio: 0.70; P=0.057), but was far less regarding overall survival (hazard ratio: 0.89). The incidence of grade 3-4 infection during consolidation (25.2% versus 14.4%) and late intensification (22.6% versus 15.9%) and the incidence of grade 2-4 allergy were higher in the long-asparaginase arm (30% versus 21%). Prolonged native E.coli asparaginase therapy in consolidation and late intensification for our non-very high risk patients did not improve overall outcome but led to an increase in infections and allergy. This trial was registered at www.clinicaltrials.gov as #NCT00003728.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 79 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 79 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Student > Master 9 11%
Other 7 9%
Student > Ph. D. Student 6 8%
Student > Doctoral Student 4 5%
Student > Bachelor 4 5%
Other 7 9%
Unknown 42 53%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 18 23%
Biochemistry, Genetics and Molecular Biology 5 6%
Nursing and Health Professions 4 5%
Neuroscience 3 4%
Psychology 2 3%
Other 3 4%
Unknown 44 56%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 October 2025.
All research outputs
#12,238,977
of 34,115,020 outputs
Outputs from Haematologica
#3,203
of 6,102 outputs
Outputs of similar age
#143,169
of 357,573 outputs
Outputs of similar age from Haematologica
#36
of 63 outputs
Altmetric has tracked 34,115,020 research outputs across all sources so far. This one is in the 38th percentile – i.e., 38% of other outputs scored the same or lower than it.
So far Altmetric has tracked 6,102 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.8. This one is in the 27th percentile – i.e., 27% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 357,573 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 63 others from the same source and published within six weeks on either side of this one. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.